Floatz logo

Sacituzumab Tirumotecan

Triple-negative Breast Cancer and HR+/HER2- BC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.antibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Triple-negative Breast Cancer and HR+/HER2- BC cohort.

Asset / SponsorPhaseRating
Kl-A167
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2CCC

Same molecule, other indications

Sacituzumab Tirumotecan is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →